6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 6 of 6 clinical reviews.
Is resmetirom effective for NAFLD without MASH? Review of clinical trial data, FDA-approved indications, off-label evidence, and what clinicians should know about prescribing Rezdiffra beyond its labeled use.
Resmetirom (Rezdiffra) is FDA-approved for MASH with fibrosis, not NAFLD broadly. Learn the off-label evidence, required lab monitoring, and clinical considerations for using resmetirom in NAFLD without significant fibrosis.
A clinical evidence summary of resmetirom (Rezdiffra) for MASH/NASH with moderate to advanced liver fibrosis (F2-F3), including MAESTRO-NASH trial data, dosing, safety, and access.
Resmetirom (Rezdiffra) is FDA-approved for NASH with F2-F3 fibrosis plus moderate-to-severe steatohepatitis. This guide covers its dosing protocol, key MAESTRO-NASH data, and practical prescribing considerations.
Evidence-based guide to off-label resmetirom (Rezdiffra) use in NASH with F2-F3 fibrosis, including monitoring protocols, clinical trial data, and safety considerations.
Resmetirom (Rezdiffra) received accelerated FDA approval for MASH with F2-F3 fibrosis in 2024. Review the MAESTRO-NASH trial data, side-effect profile, monitoring requirements, and clinical tradeoffs before starting treatment.